---
title: "Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288717735.md"
description: "Cognition Therapeutics is advancing zervimesine toward a registrational program for dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER results. The company plans a 9-month randomized study and has completed FDA engagement regarding the psychosis signal. As of March 31, 2026, the firm holds approximately $31.2 million in cash, providing a runway into Q2 2027. Additionally, its START Phase 2 trial in early Alzheimer's disease is ongoing, with topline data expected in late 2027."
datetime: "2026-06-04T12:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288717735.md)
  - [en](https://longbridge.com/en/news/288717735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288717735.md)
generator: "portal-rs"
---

# Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027

**Cognition Therapeutics advanced its oral candidate zervimesine toward a registrational program for DLB psychosis and reports cash runway into Q2 2027.**

**Key Highlights:**

-   Filed Regulation FD presentation describing plans to pursue registrational DLB psychosis development for zervimesine.
-   SHIMMER Phase 2 showed strong neuropsychiatric effects (including hallucinations and delusions); company plans a 9‑month randomized registrational study.
-   As of Mar 31, 2026 cash, equivalents & restricted cash ~$31.2M with obligated NIA grant funds $25.6M; runway into Q2 2027 per current plan.
-   FDA engagement completed: psychosis signal directed to Division of Psychiatry; meeting minutes expected June 2026 — key catalyst for next steps.
-   Ongoing START Phase 2 in early Alzheimer’s (545 pts) funded by $81M NIA grant; topline expected 2H 2027 to expand clinical insight.

Original SEC Filing: COGNITION THERAPEUTICS INC \[ CGTX \] - 8-K - Jun. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CGTX.US](https://longbridge.com/en/quote/CGTX.US.md)

## Related News & Research

- [Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis](https://longbridge.com/en/news/290686799.md)
- [Cognition Therapeutics Q2 net loss narrows on lower R&D costs](https://longbridge.com/en/news/295139858.md)
- [Neste updates financial calendar for 2027 reporting schedule](https://longbridge.com/en/news/296187781.md)
- [Cinemo, Dolby, and SmashLabs Bring In-Car Immersive Gaming Experiences to the Next Level | DLB Stock News](https://longbridge.com/en/news/296595761.md)
- [Walmart, Ross Stores, Advance Auto Parts, MARA Holdings and SpaceX: Why These 5 Stocks Are on Investors' Radars Today](https://longbridge.com/en/news/296563693.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**